RU2016146115A - Ингибитор мышечной атрофии, содержащий гликозид кверцетина - Google Patents
Ингибитор мышечной атрофии, содержащий гликозид кверцетина Download PDFInfo
- Publication number
- RU2016146115A RU2016146115A RU2016146115A RU2016146115A RU2016146115A RU 2016146115 A RU2016146115 A RU 2016146115A RU 2016146115 A RU2016146115 A RU 2016146115A RU 2016146115 A RU2016146115 A RU 2016146115A RU 2016146115 A RU2016146115 A RU 2016146115A
- Authority
- RU
- Russia
- Prior art keywords
- muscle atrophy
- muscle
- atrophy inhibitor
- inhibitor according
- triggered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Ингибитор мышечной атрофии, содержащий гликозид кверцетина.
2. Ингибитор мышечной атрофии по п.1, где ингибирование мышечной атрофии бывает запущено посредством ингибирования экспрессии Mstn.
3. Ингибитор мышечной атрофии по п.1 или 2, где ингибирование мышечной атрофии бывает запущено посредством ингибирования экспрессии по меньшей мере одного гена, выбранного из группы, состоящей из Atrogin-1, MuRF-1, Foxo1 и Redd1.
4. Ингибитор мышечной атрофии по любому из пп.1-3, где ингибитор мышечной атрофии имеет ингибирующую мышечную деградацию активность.
5. Ингибитор мышечной атрофии по п.4, где ингибирующая мышечную деградацию активность бывает запущена посредством ингибирования экспрессии по меньшей мере одного гена, выбранного из группы, состоящей из Atrogin-1, MuRF-1 и Foxo1.
6. Ингибитор мышечной атрофии по любому из пп.1-3, где ингибитор мышечной атрофии имеет стимулирующую мышечный синтез активность.
7. Ингибитор мышечной атрофии по п.6, где стимулирующая мышечный синтез активность бывает запущена посредством ингибирования экспрессии Redd1.
8. Ингибитор мышечной атрофии по любому из пп.1-7, где ингибитор мышечной атрофии предназначен для применения в предотвращении или обработке нарушенных моторных функций или моторных расстройств.
9. Ингибитор мышечной атрофии по любому из пп.1-7, где ингибитор мышечной атрофии предназначен для применения в предотвращении или обработке индуцированной лекарственным средством мышечной атрофии.
10. Композиция, содержащая ингибитор мышечной атрофии по любому из пп.1-9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014092855 | 2014-04-28 | ||
| JP2014-092855 | 2014-04-28 | ||
| PCT/JP2015/062533 WO2015166887A1 (ja) | 2014-04-28 | 2015-04-24 | ケルセチン配糖体を含有する筋萎縮抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016146115A true RU2016146115A (ru) | 2018-05-28 |
Family
ID=54358616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016146115A RU2016146115A (ru) | 2014-04-28 | 2015-04-24 | Ингибитор мышечной атрофии, содержащий гликозид кверцетина |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170042924A1 (ru) |
| EP (1) | EP3138570A4 (ru) |
| JP (2) | JP6849433B2 (ru) |
| KR (1) | KR102459500B1 (ru) |
| CN (1) | CN106255504A (ru) |
| AU (1) | AU2015254309B2 (ru) |
| CA (1) | CA2946825C (ru) |
| MY (1) | MY194893A (ru) |
| RU (1) | RU2016146115A (ru) |
| SG (2) | SG11201608760WA (ru) |
| TW (1) | TWI757228B (ru) |
| WO (1) | WO2015166887A1 (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| CA2982645C (en) * | 2015-04-27 | 2024-02-13 | Suntory Holdings Limited | Composition for suppressing muscular fatty change |
| WO2017085190A1 (en) | 2015-11-17 | 2017-05-26 | Nestec S.A. | Compositions and methods using a polyphenol for musculoskeletal health |
| WO2017186954A1 (en) * | 2016-04-28 | 2017-11-02 | Legacy Healthcare Ltd | Method for the improvement of speed and endurance capacity |
| JP2018087175A (ja) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | 筋萎縮抑制剤 |
| CA3055164A1 (en) * | 2017-03-10 | 2018-09-13 | Suntory Holdings Limited | Composition for inhibiting myofibrosis |
| WO2021033995A1 (ko) * | 2019-08-16 | 2021-02-25 | 고려제약주식회사 | 초과 추출물을 함유하는 근육 감소 관련 질병의 예방, 개선, 또는 치료용 조성물 |
| TW202216145A (zh) * | 2020-06-30 | 2022-05-01 | 日商東麗股份有限公司 | 伴隨代謝異常之疾病或症候群中的肌力低下症狀之改善劑或預防劑 |
| AU2021398645A1 (en) * | 2020-12-18 | 2023-06-29 | Suntory Holdings Limited | Composition for improving muscle flexibility |
| CN117396209A (zh) * | 2021-05-21 | 2024-01-12 | 阿尼姆斯 医药科技有限公司 | 用于预防或治疗肌肉疾病的包含桦褐孔菌醇的组合物 |
| CA3219821A1 (en) * | 2021-05-21 | 2022-11-24 | Sang-Jin Lee | Composition comprising inotodiol for prevention or treatment of muscular disease |
| JPWO2022255276A1 (ru) * | 2021-06-03 | 2022-12-08 | ||
| CN117298077B (zh) * | 2023-11-29 | 2024-02-13 | 山东海之宝海洋科技有限公司 | Trifuhalol A在改善肌肉萎缩中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1917894A (zh) * | 2004-02-10 | 2007-02-21 | 朝日啤酒株式会社 | 肌张力增强剂 |
| JP2008156294A (ja) * | 2006-12-25 | 2008-07-10 | Lion Corp | 筋芽細胞活性化剤 |
| JP2009007313A (ja) * | 2007-06-29 | 2009-01-15 | Lion Corp | 筋萎縮抑制剤 |
| JP5326246B2 (ja) | 2007-09-10 | 2013-10-30 | 国立大学法人三重大学 | 筋肉増加剤 |
| MX2012004118A (es) * | 2009-10-09 | 2012-05-08 | Nestec Sa | Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales. |
| JP2013126951A (ja) * | 2010-03-01 | 2013-06-27 | Kyushu Univ | 筋萎縮阻害剤 |
| JP6029257B2 (ja) * | 2010-06-30 | 2016-11-24 | 森永製菓株式会社 | 筋肥大促進のための食品、補助食品、及びサプリメント |
| JP2012183063A (ja) * | 2011-02-14 | 2012-09-27 | Suntory Holdings Ltd | ケルセチン配糖体配合容器詰め飲料 |
| EP2580967A1 (en) * | 2011-10-11 | 2013-04-17 | Nestec S.A. | Accelerating muscle recovery after immobilization-induced muscle atrophy |
| JP2013091608A (ja) | 2011-10-25 | 2013-05-16 | Kao Corp | ミオスタチン／Ｓｍａｄシグナル阻害剤 |
| JP5948871B2 (ja) * | 2011-12-28 | 2016-07-06 | 株式会社東洋新薬 | ポリフェノール含有組成物 |
-
2015
- 2015-04-24 RU RU2016146115A patent/RU2016146115A/ru unknown
- 2015-04-24 SG SG11201608760WA patent/SG11201608760WA/en unknown
- 2015-04-24 CA CA2946825A patent/CA2946825C/en active Active
- 2015-04-24 AU AU2015254309A patent/AU2015254309B2/en active Active
- 2015-04-24 US US15/305,680 patent/US20170042924A1/en not_active Abandoned
- 2015-04-24 MY MYPI2016703931A patent/MY194893A/en unknown
- 2015-04-24 EP EP15785738.4A patent/EP3138570A4/en not_active Withdrawn
- 2015-04-24 WO PCT/JP2015/062533 patent/WO2015166887A1/ja active Application Filing
- 2015-04-24 CN CN201580022615.7A patent/CN106255504A/zh active Pending
- 2015-04-24 KR KR1020167032953A patent/KR102459500B1/ko active IP Right Grant
- 2015-04-24 JP JP2016516356A patent/JP6849433B2/ja active Active
- 2015-04-24 SG SG10201809153WA patent/SG10201809153WA/en unknown
- 2015-04-27 TW TW104113383A patent/TWI757228B/zh active
-
2019
- 2019-09-24 JP JP2019172964A patent/JP6942165B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ725458A (en) | 2022-03-25 |
| AU2015254309B2 (en) | 2020-02-27 |
| JPWO2015166887A1 (ja) | 2017-04-20 |
| JP2019210299A (ja) | 2019-12-12 |
| SG11201608760WA (en) | 2016-11-29 |
| CN106255504A (zh) | 2016-12-21 |
| AU2015254309A1 (en) | 2016-11-10 |
| JP6849433B2 (ja) | 2021-03-24 |
| SG10201809153WA (en) | 2018-11-29 |
| MY194893A (en) | 2022-12-22 |
| KR20160146980A (ko) | 2016-12-21 |
| TWI757228B (zh) | 2022-03-11 |
| JP6942165B2 (ja) | 2021-09-29 |
| CA2946825A1 (en) | 2015-11-05 |
| EP3138570A1 (en) | 2017-03-08 |
| EP3138570A4 (en) | 2017-12-20 |
| WO2015166887A1 (ja) | 2015-11-05 |
| TW201625271A (zh) | 2016-07-16 |
| US20170042924A1 (en) | 2017-02-16 |
| KR102459500B1 (ko) | 2022-10-26 |
| CA2946825C (en) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146115A (ru) | Ингибитор мышечной атрофии, содержащий гликозид кверцетина | |
| EA033198B1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MY201783A (en) | Compositions and methods for inhibiting arginase activity | |
| UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
| IL288278A (en) | Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith | |
| WO2015200790A3 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| PH12015502588A1 (en) | 4`-fluoro-2`-methyl substituted nucleoside derivatives | |
| WO2017001936A3 (en) | Therapeutic inhibitory compounds | |
| WO2017001926A8 (en) | Therapeutic inhibitory compounds | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| ZA201707951B (en) | Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| WO2015095735A3 (en) | Vaccine compositions and uses thereof | |
| SG10201906637UA (en) | Treatment/prevention of disease by linc complex inhibition | |
| MX2017012610A (es) | Composiciones y metodos para inhibir la expresion del gen lect2. | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| WO2016048007A8 (ko) | D-갈락토오스를 포함하는 쿼럼센싱 저해제 | |
| WO2016093613A3 (ko) | 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물 | |
| WO2016178490A3 (ko) | 곰보배추 추출물 또는 이의 분획물을 포함하는 통풍 예방 또는 치료용 약학적 조성물 및 고요산혈증 개선용 식품 조성물 | |
| PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. |